A Menin Inhibitor Study
Now enrolling patients with refractory or relapsed AML
Now enrolling patients with refractory or relapsed AML
KOMET-001 (Kura Oncology Menin Inhibitor Trial) is a phase 1/2a study to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of KO-539 in patients with refractory or relapsed acute myeloid leukemia (AML).
An expansion phase in specific genetic subgroups will further evaluate antitumor activity and tolerability.
KO-539, an oral investigational drug candidate, is a novel compound targeting the menin-KMT2A (MLL) interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, KO-539 inhibits the KMT2A (MLL) protein complex and has downstream effects on HOXA9/MEIS1 expression.
of AML patients have translocations
of the KMT2A gene2
of AML patients have NPM1 mutations
with or without other gene mutations5,6
Please select a location to see sites near you
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 40411
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan Hospitals
Ann Arbor, Michigan, United States, 48109
United States, New York
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14263
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
France
Institut Gustave Roussy
Villejuif, France, 94800
For more information, please email:
KO-MEN-001@kuraoncology.com.
To talk with a medical science liaison (MSL), please email: medicalaffairs@kuraoncology.com.
REFERENCES: 1. Kühn MW, Song E, Feng Z et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 2016;6(10):1166–1181. 2. Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130(2):981-997. 3. Chan AKN, Chen CW. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Front Cell Dev Biol. 2019;7:81. 4. Burrows F, Wu T, Kessler L, et al. A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML [abstract]. In: Proceedings of the AACR EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl): Abstract nr LB-A27. 5. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011-4020. 6. Prata PH, Bally C, Prebet T, et al. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica. 2018;103(10):e455-e457.